



Q1 2020 RESULTS



“ I am proud of the way Sanofi employees have responded to the immense challenges of the COVID-19 pandemic. They continue to put patients first while embracing and delivering on the new Company strategy. ”

PAUL HUDSON

CHIEF EXECUTIVE OFFICER, SANOFI

COMPANY SALES & BUSINESS EPS*

Q1 2020 SALES*
€8,973M
+6.6% (+6.9%)

Q1 2020 BUSINESS EPS*
€1.63
+15.6% (+15.6%)

*Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis.

SALES BY GLOBAL BUSINESS UNIT


€2,695M
Speciality Care


€909M
Vaccines


€4,069M
General Medicines


€1,300M
Consumer Healthcare

SALES BY GEOGRAPHY

U.S.
€2,971M

EUROPE
€2,382M

REST OF THE WORLD
€3,620M

of which:
China: **€680M**
Japan: **€505M**
Brazil: **€270M**
Russia: **€194M**

SANOFI AT FOREFRONT OF FIGHT AGAINST COVID-19



Developing vaccines and treatments

3 collaborations to develop novel COVID-19 vaccines

2 existing treatments evaluated

1 partnership to develop smartphone-based self-testing solution



Supporting patients, healthcare workers and health authorities

Commitment to donate **100 million doses** of anti-viral treatment



Ensuring continuous manufacturing and delivery of essential medicines and vaccines

20,000 employees working every day in all industrial sites

100% of manufacturing sites operational

R&D HIGHLIGHTS

87

projects in development, including 35 new molecular entities & additional indications



39

projects in Phase 3 or submitted for approval



For further information on Q1 2020 results and definitions of financial indicators, please refer to the press release issued on April 24, 2020 at:

<https://www.sanofi.com/en/investors>



Sanofi.com

Sanofi.us



@Sanofi



Sanofi



@Sanofi



@SanofiUS



SanofiUS